CAR-T cell therapy has shown remarkable promise in treating B-cell malignancies, which
has sparked optimism about its potential to treat other types of cancer as well. Nevertheless …

The treatment of human immunodeficiency virus (HIV-1) has evolved since the
establishment of combination antiretroviral therapy (ART) in the 1990s, providing HIV …

Allogeneic invariant natural killer T cells (allo-iNKTs) induce clinical remission in patients
with otherwise incurable cancers and COVID-19-related acute respiratory failure. However …

Advances in understanding the genetic basis of cancer have driven alternative treatment
approaches. Recent findings have demonstrated the potential of bacteria and it's …

The concept of chimeric antigen receptor (CAR) T cell therapy emerged from cancer
immunotherapy and has been rapidly adapted and developed for the treatment of …

The management of autoimmune diseases is currently limited by therapies that largely
suppress the immune system, often resulting in partial and temporary remissions. Cellular …

Adoptive cellular therapy using chimeric antigen receptors (CAR) has transformed
immunotherapy by engineering T cells to target specific antigens on tumor cells. As the field …

Abstract The demand for Lentiviral Vector (LV) drug substance is increasing. However,
primary capture using convective anion‐exchange chromatography remains a significant …

Lung cancer remains one of the leading causes of cancer-related mortality worldwide
necessitating the development of innovative therapeutic strategies. Chimeric antigen …

The concept of time toxicity in oncology refers to the presence of frequent healthcare-related
interactions that can interfere with patient well-being. In this review, we examine several …